Overuse testing by recruitment site and tumor type
tumor, colorectal, breast cancer, cancer, cancer type
CANCER, TUMOR, BREAST CANCER
Of the 140 cancer‐related tests ordered that were not recommended on SCPs (including tumor markers), 91% (90/99) at the community site were consistent with overuse and 20% (8/41) at the academic site were consistent with overuse. The majority of testing consistent with overuse at the community site (78/90, 87%) was related to laboratory testing. Excluding laboratory testing, 57% (12/21) of imaging tests performed at the community site were consistent with overuse. In contrast, the academic site performed no lab testing consistent with overuse, although 20% (8/41) of cancer‐related imaging at the academic site was consistent with overuse. By cancer type, the rate of testing consistent with overuse was most common for breast cancer patients at the community site (18/65, 28%) and for colorectal patients at the academic site (4/46, 9%) (Table Frequency and percentage of cancer survivors with overuse by study site and cancer type